Nexus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEXUS, and what generic alternatives to NEXUS drugs are available?
NEXUS has twenty approved drugs.
There are five US patents protecting NEXUS drugs. There is one tentative approval on NEXUS drugs.
There are ten patent family members on NEXUS drugs in nine countries and eighty-eight supplementary protection certificates in nine countries.
Drugs and US Patents for Nexus
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nexus Pharms | FLUORESCEIN SODIUM | fluorescein sodium | INJECTABLE;INTRAVENOUS | 215709-001 | Sep 25, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Nexus | COLISTIMETHATE SODIUM | colistimethate sodium | INJECTABLE;INJECTION | 065177-001 | Mar 19, 2004 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Nexus | NELARABINE | nelarabine | INJECTABLE;INTRAVENOUS | 215057-001 | Jun 2, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-002 | Feb 28, 2023 | RX | Yes | Yes | 11,464,752 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Nexus | TIROFIBAN HYDROCHLORIDE | tirofiban hydrochloride | SOLUTION;INTRAVENOUS | 213947-002 | Jul 24, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | RX | Yes | Yes | 11,464,752 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nexus Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 113825500 | ⤷ Try a Trial |
South Korea | 20220009985 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2020232424 | ⤷ Try a Trial |
Canada | 3140043 | ⤷ Try a Trial |
European Patent Office | 3968975 | ⤷ Try a Trial |
Japan | 2023091072 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nexus Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1499331 | 13C0055 | France | ⤷ Try a Trial | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
2822954 | 1890030-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
1713823 | 1490064-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
2203431 | 92666 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
2380576 | 20C1048 | France | ⤷ Try a Trial | PRODUCT NAME: SEL DE SODIUM DE L'ACIDE DESOXYCHOLIQUE; NAT. REGISTRATION NO/DATE: NL46299 20180810; FIRST REGISTRATION: IS - IS/1/16/071/01 20160729 |
2203431 | 15C0013 | France | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.